Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I–IIIB small-cell lung cancer
Abstract Background To date, there remains a paucity of comparative investigations pertaining to preoperative immunochemotherapy and conventional chemotherapy in the context of limited-stage small-cell lung cancer (LS-SCLC) patients. This study conducted a comprehensive comparative assessment concer...
Saved in:
Main Authors: | Linhai Zhu, Jiacong Liu, Xuhua Huang, Jian Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-024-13405-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
by: Yingyi Li, et al.
Published: (2025-02-01) -
Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study
by: Li Sun, MD, et al.
Published: (2025-02-01) -
Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study
by: Zhi Yang, et al.
Published: (2025-01-01) -
Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer
by: Ning Zhang, et al.
Published: (2025-01-01) -
Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
by: Yuchen Wang, et al.
Published: (2025-01-01)